Abstract:1. CNBP is associated with poor prognosis and clinical progression of neuroblastoma. 2. KPNB1 facilitates nuclear translocation of CNBP to interact with SMARCC2 in liquid condensates. 3. CNBP modulates SWI/SNF activity via SMARCC2 to drive ribosome biogenesis of neuroblastoma cells and subsequent M2 macrophage polarisation. 4. Therapeutic targeting of phase separation and interaction of CNBP with SMARCC2 inhibits neuroblastoma progression. Background Neuroblastoma (NB) is the most common extracranial malignancy in childhood; however, the mechanisms underlying its aggressive characteristics still remain elusive. Methods Integrative data analysis was performed to reveal tumour‐driving transcriptional regulators. Co‐immunoprecipitation and mass spectrometry assays were applied for protein interaction studies. Real‐time reverse transcription‐polymerase chain reaction, western blotting, sequential chromatin immunoprecipitation and dual‐luciferase reporter assays were carried out to explore gene expression regulation. The biological characteristics of NB cell lines were examined via gain‐ and loss‐of‐function assays. For survival analysis, the Cox regression model and log‐rank tests were used. Results Cellular nucleic acid‐binding protein (CNBP) was found to be an independent factor affecting NB outcome, which exerted oncogenic roles in ribosome biogenesis, tumourigenesis and aggressiveness. Mechanistically, karyopherin subunit beta 1 (KPNB1) was responsible for nuclear transport of CNBP, whereas liquid condensates of CNBP repressed the activity of switch/sucrose‐nonfermentable (SWI/SNF) core subunits (SMARCC2/SMARCC1/SMARCA4) via interaction with SMARCC2, leading to alternatively increased activity of SMARCC1/SMARCA4 binary complex in facilitating gene expression essential for 18S ribosomal RNA (rRNA) processing in tumour cells, extracellular vesicle‐mediated delivery of 18S rRNA and subsequent M2 macrophage polarisation. A cell‐penetrating peptide blocking phase separation and interaction of CNBP with SMARCC2 inhibited ribosome biogenesis and NB progression. High KPNB1, CNBP, SMARCC1 or SMARCA4 expression or low SMARCC2 levels were associated with poor survival of NB patients. Conclusions These findings suggest that CNBP phase separation is a target for inhibiting ribosome biogenesis and tumour progression in NB via modulating SWI/SNF complex activity.

Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN

Yap Promotes The Proliferation Of Neuroblastoma Cells Through Decreasing The Nuclear Location Of P27(Kip1) Mediated By Akt

CCNB1IP1 prevents ubiquitination-mediated destabilization of MYCN and potentiates tumourigenesis of <i>MYCN</i>-amplificated neuroblastoma

CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma

CCNB1IP1 stabilizes MYCN through suppression of Fbxw7-mediated degradation and facilitates the growth of MYCN-amplified neuroblastoma

BRD4 Inhibitor MZ1 Exerts Anti-Cancer Effects by Targeting MYCN and MAPK Signaling in Neuroblastoma.

P300 Interacted with N-Myc and Regulated Its Protein Stability Via Altering Its Post-Translational Modifications in Neuroblastoma

BAP1 loss augments sensitivity to BET inhibitors in cancer cells

KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m6A reader YTHDC1 protein degradation

P300 interacted with N-Myc and regulated its protein stability via altering its posttranslational modifications in neuroblastoma

Bmi-1 is Essential for the Tumorigenicity of Neuroblastoma Cells

MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma

Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN

BAP1 loss confers sensitivity to bromodomain and extra-terminal inhibitors in renal cell carcinoma

The Deubiquitinase USP28 Maintains the Expression of the Transcription Factor MYCN and is Essential in Neuroblastoma Cells.

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN -amplified neuroblastoma

Therapeutic targeting of CNBP phase separation inhibits ribosome biogenesis and neuroblastoma progression via modulating SWI/SNF complex activity

Loss of nuclear envelope phosphatase CTDNEP1 drives aggressive medulloblastoma by triggering MYC amplification and genomic instability

The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma

Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability

TAF1D promotes proliferation by transcriptionally activating G2/M phase‐related genes in MYCN‐amplified neuroblastoma